Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended December 31, 2025
Business Overview: A medical technology company developing non-invasive testing solutions, primarily the Intelligent Fingerprinting (IFP) Drug Screening System. The company operates globally with segments in the United Kingdom, APAC, Americas, and Rest of World.
Corporate Action: A 1-for-10 reverse stock split was effected on December 15, 2025, to regain compliance with Nasdaq listing requirements. All share and per-share data in this summary reflect this adjustment.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2025 |
|---|---|---|
| Revenue | $896,774 | $2,008,571 |
| Gross Profit | $459,739 | $978,030 |
| Gross Margin | 51.3% | 48.7% |
| Net Loss (Attributable to INBS) | $(2,677,590) | $(5,660,596) |
| Net Loss Per Share (Basic/Diluted) | $(2.82) | $(6.27) |
| Cash and Cash Equivalents | $740,371 (as of Dec 31, 2025) | |
| Working Capital | $7,047,443 (as of Dec 31, 2025) | |
| Total Liabilities | $6,763,231 (as of Dec 31, 2025) |
Non-GAAP Contribution Margin: For the six months ended Dec 31, 2025, the contribution margin was $1,469,657 (73.17% of revenue), driven by improved sales mix favoring high-margin cartridges.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 47.6% year-over-year for the quarter ($896,774 vs. $607,494) and 35.7% for the six-month period ($2,008,571 vs. $1,479,781). Growth was driven by the addition of 17 new customers in the quarter and 49 in the six-month period, alongside increased reorder rates for consumables.
- Profitability: Gross profit increased significantly, with gross margin improving to 48.7% for the six-month period (from 38.5% in the prior year). This was aided by operational efficiencies and the capitalization of certain direct labor costs related to software development.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 29.2% for the quarter and 33.0% for the six-month period, primarily due to increased marketing spend, legal fees for capital raising and the reverse stock split, and higher wages for finance and marketing staff.
- Impairment: The company recorded an impairment of long-lived assets of $27,147 for the quarter and $288,927 for the six-month period, related to construction in progress assets held for sale.
- Government Support: Government support income decreased 45.6% for the quarter ($72,720 vs. $133,640) due to changes in U.K. R&D tax credit legislation reducing the benefit rate from 14.5% to 10%.
Guidance, Outlook, Risks, and Unusual Items
Capital Raising and Liquidity
- December Private Placement: On December 31, 2025, the company entered into a private placement agreement for gross proceeds of approximately $10.0 million. The transaction closed on January 2, 2026, with proceeds of $9,402,105 recorded as a subscription receivable at period-end.
- ATM Offering: The company raised approximately $1.16 million during the quarter via its At-The-Market (ATM) offering program.
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional financing. While the private placement provides significant liquidity, the company expects to continue incurring operating losses.
Strategic Developments
- Manufacturing Partnership: Announced a strategic partnership with Syrma Johari MedTech Ltd. to scale production, targeting a 40% reduction in annual production costs and a 20 percentage point improvement in gross profit.
- Strategic Alliance: Entered a collaboration with Vlepis Pty Ltd. to expand into consumer health monitoring and wearable technologies.
Risks and Contingencies
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of December 31, 2025, due to material weaknesses in the control environment, risk assessment, and monitoring. Remediation efforts include implementing a new accounting system (NetSuite) and hiring additional finance personnel.
- Australian Grant Repayment: Following an audit, the company owes approximately $2.1 million to the Australian Government regarding a manufacturing facility grant. Failure to repay could result in defaults or enforcement actions.
- Intellectual Property: Risks exist regarding the licensing of Biosensor IP from the University of Newcastle, as the previous licensor (LSBD) is in liquidation. Finalization of terms is pending the completion of the liquidation process.
Investor Verification Checklist
- Subscription Receivable Realization: Verify the receipt of the $9.4 million from the December Private Placement (noted as received Jan 2, 2026) and confirm the cash balance in subsequent filings.
- Going Concern Status: Monitor the company's ability to secure additional funding beyond the recent private placement to cover operating losses and the $2.1 million Australian grant repayment.
- Internal Control Remediation: Track progress on the implementation of the new accounting system and the hiring of finance staff to address the material weaknesses in internal controls.
- Revenue Concentration: Note that one customer accounted for 21.6% of revenue in the quarter; monitor for changes in this concentration risk.
- Regulatory Progress: Follow updates on the FDA 510(k) submission and the status of the Biosensor IP licensing negotiations with the University of Newcastle.